Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite the development of multimodal therapy. Expression of glypican-1 (GPC1) has been reported to be elevated in a subset of patients with ESCC and associated with chemoresistance. This study aimed to determine the association of GPC1...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2017-04, Vol.8 (15), p.24741-24752
Hauptverfasser:	Harada, Emi, Serada, Satoshi, Fujimoto, Minoru, Takahashi, Yusuke, Takahashi, Tsuyoshi, Hara, Hisashi, Nakatsuka, Rie, Sugase, Takahito, Nishigaki, Takahiko, Saito, Yurina, Hiramatsu, Kosuke, Nojima, Satoshi, Mitsuo, Risa, Ohkawara, Tomoharu, Morii, Eiichi, Mori, Masaki, Doki, Yuichiro, Kaneda, Yasufumi, Naka, Tetsuji
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - pathology Cell Line, Tumor Cell Proliferation Esophageal Neoplasms - genetics Esophageal Neoplasms - pathology Esophageal Squamous Cell Carcinoma Female Glypicans - metabolism Humans Male Research Paper Transfection
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!